Document is current

Article History

Received: 7 May 2024

Accepted: 2 September 2024

First Online: 19 September 2024

Declarations

:

: This retrospective case series was in accordance with good clinical practice protocols and adhered to the tenets of the Declaration of Helsinki. Informed verbal and written consent was obtained from the patients for the publication of this report. Sterling IRB determined our series was exempt from IRB review (reference # 12292-RSisk) due to the low-risk nature of the retrospective study.

: Consent was requested and obtained from the patients for study inclusion.

: Robert A. Sisk: consultant for AGTC/Beacon, Ascidian, EyePoint, Gyroscope, Iveric Bio, Leica Microsystems, Novartis, Orbit Biomedical, Oxular, and RegenxBio. Daniel F. Kiernan: speaker’s bureau for Alimera, Allergan/AbbVie, Bausch & Lomb, Coherus, EyePoint, Harrow, Mallinckrodt, Novartis, Notal Vision, Physician Recommended Nutraceuticals, and Regeneron. Consultant for Allergan/AbbVie, Bausch + Lomb, Coherus, EyePoint, Mallinckrodt, Physician Recommended Nutraceuticals, and Regeneron. Received grant support from Allergan/ Abbvie, EyePoint, Gyroscope, and Opthea. David Almeida: consultant for Alcon, Alimera, Allergan/AbbVie, Genentech, and Regeneron. Has received financial support (funding, grants, research materials, or in-kind services) from Acylerin, Alcon, Alimera, Allergan/AbbVie, Bausch + Lomb, Bayer, Boehringer Ingelheim, Dutch Ophthalmics, EyePoint, Genentech, Gyroscope, Novartis, Ocugen, Opthea, Regeneron, RegenexBio, Roche, and Samara Vision. Has personal financial interest in Citrus Therapeutics (cofounder), Erie Retina Research (President & CEO), Element: Reading Center (President & CEO), Access for All (Non-profit; chairman of the board), KPeye (President & CEO), React: Research in Advanced Technologies (cofounder & managing partner), and ACT: Applied Clinical Technologies (cofounder and managing partner). Anton M. Kolomeyer: consultant for Alimera, Allergan, Apellis, Biogen, Genentech, Iveric (Astellas), and Regeneron. Speaker for Biogen, Genetech, and Iveric (Astellas). David Eichenbaum: consultant for Alimera, Allergan, Annexon, Appelis, Bausch + Lomb, Coherus, Crinetics, Eyepoint, Genentech, IvericBio, Kodiak, Novartis, Ocuphire, Opthea, Outlook, Ocular Therapeutix, RecensMedical, Regeneron, RegenexBio, ReVive, Samsara, and Vestrum/CorEvitas. Speaker for Allergan, Apellis, Bayer, Genentech, IvericBio, Novartis, and Regeneron. Investigator for 4DMT, Aerie/Alcon, Alexion, Allegenesis, Annexon, Aviceda, Bayer, EyeBio, EyePoint, Gemini, Genentech, Gyroscope, Ionis, IvericBio, Janssen, Kodiak, Mylan, NGM, Janssen, Novartis, Ocular Therapeutix, Opthea, RecensMedical, Regeneron, RegenxBio, ONL, and Unity. Holds equity/ is a stockholder in the Boston Image Reading Center, Janssen, Network Eye, ReVive, and US Retina. Founder of Network Eye. John W. Kitchens: consultant for Alcon, Allergan, Alimera, Apellis, Astellas, Bayer, Biogen, Bausch + Lomb, Genentech, Kodiak Bioscience, Notal Vision, Optos, Oculus, Outlook, Regeneron, Roche, and Zeiss. Speaker for Alcon, Bayer, Genentech, and Regeneron. Owns stock in Regeneron.